Алкогольний фіброз печінки: сучасний стан проблеми
Ключові слова:
печінка, фіброз, алкогольний фіброз печінки, зірчасті клітини, цитокіни, «Гепаризин»Анотація
Представлено дані щодо патогенетичних механізмів розвитку фіброгенезу та алкогольного фіброзу печінки. Визначено чинники прогресування та звортності хвороби. Показано роль препарату «Гепаризин» як комбінованого гепатопротектора, який має антифібротичну активність, протизапальну, мембранопротекторну, антиоксидантну і антитоксичну дію.Посилання
Balashova AA. Rol’ immuno-vospalitel’nyh izmenenij v otsenke alkogol’nogo porazheniya pecheni [The role of immune-inflammatory changes in the evaluation of alcoholic liver damage].Аbstract of thesis of dis. … of cand. мed. sciences. (Russian). М., 2017.
Golovanova EV. Mechanisms of fibrosis in chronic liver diseases and the possibility of antifibrotic therapy (Russian) Соnsilium Medicum [Соnsilium physician](Russian). 2014;8:52-59.
Zvyagintseva TD, Chernobay AI. Modern views on the problem of noncirrhotic liver fibrosis (Russian)Mistectvo licuvannуа [Art of treatment] (Ukrainian). 2017;6/7:4-14.
Zvyagintseva TD, Chernobay AI New possibilities of hepatoprotection for non-alcoholic and alcoholic steatohepatitis (Russian). Рraktykujuchyj licar [Practicing doctor] (Ukrainian). 2015;1:46-53.
Zvyagintseva TD, Chernobay AI, Kharchenko NV. Khronicheskie zabolevaniya pecheni. Rukovodstvo dlya vrachej. 3-e izd. Chronic liver diseases. A guide for doctors. 3rd ed. (Ukrainian). Kharkiv: Printing house Madrid, 2016:260.
Ivashkin V, T., Pavlov CS. Fibros pecheni [Fibrosis of the liver] (Russian). M.: Geotar-Media, 2011:168.
Korsunskaya IM, Piruzyan AL, Sakaniya LR et al. The role of glycyrrhizic acid in the pathogenesis of psoriatic disease. Effectivnaya farmacoterapiуа[Effective pharmacotherapy]. (Russian). 2016;13:24-31.
Kurysheva MA. Fibrosis of the liver: past, present, future. RMJ [RMJ]. (Russian). 2010;28:1713-1717.
Nikitin IG, Baikova IE, Volynkina VM et al. Experience in the use of glycyrrhizic acid in the treatment of patients with alcoholic liver disease RJGGC [RJGGC]. (Russian). 2009;1, Т. 19:53-58.
Orlov Yu.V., Sinyachkin DA, Khalimov Yu.S. et al. Modern state of the problem of treatment of toxic hepatitis and liver fibrosis Gepatologiya [Hepatology]. (Russian). 2017;18:488-513.
Hookhlina OS, Antonov AA, Mandryk OE. Influence of glycyrhizin in combination with glycine and methionine on the state of extracellular matrix components in patients with non-alcoholic steatohepatitis due to the comorbidity of the matrix and the intensity of liver fibrosis in patients with non-alcoholic steatohepatitis for comorbidity with chronic kidney disease Suchasna gastroenterologiya [Modern gastroenterology]. (Ukrainian). 2017;5 (97):29-33.
Chernyavsky VV. Inflammatory process in chronic liver diseases: possible therapeutic approaches Рraktykujuchyjlicar [Practicing doctor] (Ukrainian). 2013;3:38-42.
Alba R, Compare D, Angrisani D et al. Alcoholic disease: liver and beyond. World J Gastroenterol. 2014;20 (40):14652-14659.
Christian Trautwein L, Friedman S, Schuppan D et al. Hepatic fibrosis: concept to treatment. J Hepatol. 2015;62:15-24.
Chuan-tao Tu, Jing Li, Fu-ping Wang et al. Glycyrrhizin regulates CD4+T cell response during liver fibrogenesis via JNK, ERK and PI3K/AKT pathway. Intern Immunopharmacol. 2012;14:410-421.
Fiore C, Eisenhut M, Krausse R et al. Antiviral effects of Glycyrrhiza species. Phytother Res. 2008;22:141-148.
Hanafy АS. Non-invasive assessment of fibrosis progression in non-alcoholic fatty liver disease. J Hepatol. 2016;64(2):473.
Julie P, Neil Guha I, Harris S. Systematic review of the diagnostic performance of serum markers of liver fibrosis in alcoholic liver disease. Comparative Hepatol. 2012;1:1-15.
Jian-yuan Li, Hong-yan Cao, Ping Liu et al. Glycyrrhizic acid in the treatment of liver diseases: Literature review. Biomed Res Int. 2014;2014. 872139.
Kumada H. Long-term gtreatment of chronic hepetitis C with glycyrrhizin (SNMC) for preventis liver chirrosis and hepatocellular carcinoma. Oncol. 2002;62:94-100.
Lee UE, Friedman SL. Mechanisms of hepatic fibrogenesis. Clin Gastroenterol. 2011;25:195-206.
Lech C, Panasiuk A. Liver fibrosis markers in alcoholic liver disease. World J Gastroenterol. 2014;20 (25):8018-8023.
Li JY, Cao HY, Liu P et al. Glycyrrhizic acid in the treatment of liver diseases: literature review. Biomed Res Int. 2014;872139.
Liver fibrosis: The next goal of targeted therapy?. EASL Monothematic Conference (Porto, Portugal, 17-18 June, 2016):181.
Meng Wei, Yu Liang-zhu,Wang L. Effects of compound glycyrrhizin on liver function in patients with alcoholic liver disease:a meta-analysis. China Pharmacy. 2013;12:108-115.
Naveau S, Essoh BM, Ghinoiu M et al. Comparison of Fibrotest and PGAA for the diagnosis of fibrosis stage in patients with alcoholic liver disease. Eur J GastroenterolHepatol. 2014;26, N 4:404-411.
Pragati L, Ganesh KB, Kothiyal P. Hepatic stellate cells as a target for the treatment of liver fibrosis. Int J Pharma Res. 2015;4(7):32-37.
Scott LF. Mechnisms of hepatic fibrogenesis. Gastroenterol. 2008;134(6):1655-1669.
Yue Sihong. Treatment of liver cirrhosis with compound glycyrrhizin (252 cases). J Binzhou Medical College. 1998;21(6):556.
Wang Juntao, Yu Shaojun, Xiao Wei Clinical application of compound glycyrrhizin in liver diseases. J China Pharm. 2002;13(8):500-501.
Znanje Znanje. The improvement function of compound glycyrrhizin (SNMC) on liver function in patients with cirrhosis. Acta Academiae Medicinae Nei Мongol. 2004;26:1-6.
